UNDERSTANDING PREFERENCES FOR TYPE OF TAKE-HOME NALOXONE DEVICE: INTERNATIONAL QUALITATIVE ANALYSIS OF THE VIEWS OF PEOPLE WHO USE OPIOIDS.
Consumer behaviour
Iterative Categorization
Naloxone
Overdose
Qualitative
Usage situation
Journal
Drugs (Abingdon, England)
ISSN: 0968-7637
Titre abrégé: Drugs (Abingdon Engl)
Pays: England
ID NLM: 9515845
Informations de publication
Date de publication:
2022
2022
Historique:
entrez:
11
7
2022
pubmed:
12
7
2022
medline:
12
7
2022
Statut:
ppublish
Résumé
Take-home naloxone (THN) is provided to non-medically trained people to reverse potential opioid overdoses. There is an increasing range of effective intramuscular (IM) and intranasal (IN) naloxone devices and this paper explores the types preferred by people who use opioids, using consumer behaviour literature to interpret the findings. Data derive from two unconnected qualitative studies involving audio-recorded semi-structured interviews. Study 1 was conducted in the United States (n=21 users of non-medical/illicit opioids). Study 2 was conducted in Australia (n=42 users of non-medical/illicit or prescribed opioids). Most participants preferred IN naloxone. Preferences were based on the ease, speed, safety and comfort of each device and underpinned by accounts of overdose revivals as being very rushed and frightening situations. Preferences related to complex interactions between the naloxone device ('product'); the knowledge, skills, experience and attitudes of the lay responder ('consumer'), and when, where and how naloxone was to be used ('usage situation'). THN programs should offer choice of device when possible and nasal naloxone if resources permit. Asking people which devices they prefer and why and treating them as valued consumers of naloxone products can generate insights that improve future naloxone technology and increase THN uptake and usage.
Sections du résumé
Background
UNASSIGNED
Take-home naloxone (THN) is provided to non-medically trained people to reverse potential opioid overdoses. There is an increasing range of effective intramuscular (IM) and intranasal (IN) naloxone devices and this paper explores the types preferred by people who use opioids, using consumer behaviour literature to interpret the findings.
Methods
UNASSIGNED
Data derive from two unconnected qualitative studies involving audio-recorded semi-structured interviews. Study 1 was conducted in the United States (n=21 users of non-medical/illicit opioids). Study 2 was conducted in Australia (n=42 users of non-medical/illicit or prescribed opioids).
Findings
UNASSIGNED
Most participants preferred IN naloxone. Preferences were based on the ease, speed, safety and comfort of each device and underpinned by accounts of overdose revivals as being very rushed and frightening situations. Preferences related to complex interactions between the naloxone device ('product'); the knowledge, skills, experience and attitudes of the lay responder ('consumer'), and when, where and how naloxone was to be used ('usage situation').
Conclusions
UNASSIGNED
THN programs should offer choice of device when possible and nasal naloxone if resources permit. Asking people which devices they prefer and why and treating them as valued consumers of naloxone products can generate insights that improve future naloxone technology and increase THN uptake and usage.
Identifiants
pubmed: 35813841
doi: 10.1080/09687637.2021.1872499
pmc: PMC9268211
mid: NIHMS1674354
doi:
Types de publication
Journal Article
Langues
eng
Pagination
109-120Subventions
Organisme : NIDA NIH HHS
ID : R01 DA035207
Pays : United States
Références
Eur J Clin Pharmacol. 2017 May;73(5):555-562
pubmed: 28144724
N Engl J Med. 2020 May 28;382(22):2129-2136
pubmed: 32459923
Addict Sci Clin Pract. 2017 Jan 7;12(1):4
pubmed: 28061909
Addiction. 2019 May;114(5):859-867
pubmed: 30644628
Addiction. 2019 Apr;114(4):708-718
pubmed: 30476356
Emerg Med J. 2005 Sep;22(9):612-6
pubmed: 16113176
Addiction. 2016 Apr;111(4):574-82
pubmed: 26840916
Ann Intern Med. 1999 Apr 6;130(7):584-90
pubmed: 10189329
J Am Pharm Assoc (2003). 2017 Mar - Apr;57(2S):S19-S27.e4
pubmed: 28214219
J Addict Nurs. 2016 Jul-Sep;27(3):160-79
pubmed: 27580190
Addiction. 2013 Dec;108(12):2141-9
pubmed: 23919595
JAMA Netw Open. 2019 Nov 1;2(11):e1914977
pubmed: 31722024
N Z Med J. 2012 Jun 29;125(1357):76-87
pubmed: 22854362
BMJ. 1996 Jun 8;312(7044):1435-6
pubmed: 8664611
Harm Reduct J. 2006 Jul 05;3:19
pubmed: 16822302
J Pharm Pract. 2018 Feb;31(1):91-98
pubmed: 28399697
Drugs. 2019 Sep;79(13):1395-1418
pubmed: 31352603
Int J Drug Policy. 2015 Jan;26(1):92-9
pubmed: 25130869
Addiction. 2009 Dec;104(12):2067-74
pubmed: 19922572
Sociol Health Illn. 2019 Feb;41(2):427-443
pubmed: 30710415
J Subst Abuse Treat. 2006 Mar;30(2):129-33
pubmed: 16490676
Med J Aust. 2005 Jan 3;182(1):24-7
pubmed: 15651944
Drug Alcohol Depend. 2017 Sep 1;178:176-187
pubmed: 28654870
Prev Med. 2018 Sep;114:79-87
pubmed: 29908763
Health Serv Res. 1999 Dec;34(5 Pt 2):1189-208
pubmed: 10591279
J Clin Pharmacol. 2016 Oct;56(10):1243-53
pubmed: 27145977
Addiction. 2017 May;112(5):911-912
pubmed: 28244244
J Subst Abuse Treat. 2020 Oct;117:108099
pubmed: 32811629
Addiction. 2018 Mar;113(3):484-493
pubmed: 29143400
J Adv Nurs. 1997 Oct;26(4):664-71
pubmed: 9354976
Addict Behav. 2018 Nov;86:56-60
pubmed: 29625751
Subst Abus. 2016;37(1):42-6
pubmed: 26682929
J Urban Health. 2008 May;85(3):352-60
pubmed: 18347990
Health (London). 2022 Mar;26(2):139-161
pubmed: 32529843
Addiction. 2015 Oct;110(10):1644-52
pubmed: 26119038
Addiction. 2016 Jun;111(6):1096-106
pubmed: 26806155
Am J Public Health. 2015 Nov;105(11):e29-49
pubmed: 26451760
Addiction. 2014 Feb;109(2):250-9
pubmed: 24103087
ANS Adv Nurs Sci. 1986 Apr;8(3):18-26
pubmed: 3083764
J Community Health. 2013 Feb;38(1):133-41
pubmed: 22847602
Drug Alcohol Depend. 2016 Jun 01;163:16-23
pubmed: 26996745
Subst Abus. 2015;36(2):240-53
pubmed: 25774771
BMJ. 2013 Jan 30;346:f174
pubmed: 23372174
Int J Drug Policy. 2018 Aug;58:46-54
pubmed: 29803097
Acad Emerg Med. 1996 Jul;3(7):660-7
pubmed: 8816181
Pharmacoeconomics. 2002;20 Suppl 3:1-10
pubmed: 12457421
Addiction. 2021 Mar;116(3):668-676
pubmed: 32926762
Drug Alcohol Depend. 2015 Dec 1;157:112-20
pubmed: 26507172